Policy WatchMarch 14, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal...
This Week in Cannabis: March 14, 2026
Weekly RoundupThis week, cannabis coverage focused on clinical research outcomes, legalization policy developments, and regulatory scheduling changes. **Dominant themes:** (1) Therapeutic applications and clinical trials for CBD/cannabinoids; (2) State-level legalization efforts and...
CED Digest: 436 Items — March 14, 2026
CED DigestMarch 14, 2026. 436 items curated for clinical relevance. Above Threshold #97Alabama Medical Cannabis Sales Gear for Spring 2026 Launch# Summary Alabama's medical cannabis program is preparing to begin patient sales...
Policy Watch: 17 Regulatory Updates — March 14, 2026
Policy WatchMarch 14, 2026. 17 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don't see a summary provided...
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Clinical Summary This notice documents the Drug Enforcement Administration's...
Definition of Engaged in the Business as a Dealer in Firearms
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyIndustry Why This Matters I appreciate you wanting me to...
Schedules of Controlled Substances: Rescheduling of Marijuana
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyResearchTHCSafety Why This Matters I don't see a summary provided...
Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters This action temporarily schedules isotonitazene analogs...
Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyResearchIndustry 💬 Join the Conversation Have a question about how...